I found this message from M.Reich in the tdr-scientists newsgroup and think that
it might be of interest to our newsgroup, too.
A new report is available on policy issues related to Praziquantel, and is
The report can be obtained on-line from the World Wide Web, at:
INTERNATIONAL STRATEGIES FOR TROPICAL DISEASE TREATMENTS:
EXPERIENCES WITH PRAZIQUANTEL
by Michael R. Reich, Ramesh Govindaraj, Karin Dumbaugh, Bong-min
Yang, Agnes Brinkmann, and Sameh El-Saharty, with the assistance
of Christopher Mast and John Norris.
This report identifies national and international policies that
have facilitated or hindered the availability of praziquantel,
the drug of choice for all forms of schistosomiasis occurring in
humans. The report gives particular attention to questions of
access for people in the world's poorest countries in Africa
where schistosomiasis is endemic. The analysis of praziquantel
illustrates more general problems in the design of national and
international policies for tropical disease products, and
suggests strategies for future research and action.
The report's seven chapters are:
Chapter 1: Policies for Praziquantel: An Overview;
Chapter 2: Bayer & E. Merck: Discovery and Development of
Chapter 3: Shin Poong Pharmaceutical Co.: Process Development in
Chapter 4: Egyptian International Pharmaceutical Industries Co.:
Chapter 5: The International Supply of Praziquantel;
Chapter 6: Demand for Praziquantel and National Distribution; and
Chapter 7: Prices and Production Costs for Praziquantel.
This research project was carried out through the Takemi Program
in International Health, at the Harvard School of Public Health
(665 Huntington Avenue, Boston, MA, USA 02115), with the
financial support of the Edna McConnell Clark Foundation.
Comments on the report are appreciated, and can be sent to:
reich at hsph.harvard.edu
Genetische Parasitologie des
Instituts fuer Genetik der
Fax : 49-211-81-12333
Fax : 49-211-81-12279
e-mail: Christoph.Grevelding at uni-duesseldorf.de